Valuation: Simcere Pharmaceutical Group Limited

Market Cap 3.96B 3.46B 3.2B 2.95B 5.6B 378B 5.69B 38.18B 14.99B 186B 14.87B 14.55B 640B P/E 2026 *
16x
P/E 2027 * 13.5x
Enterprise Value 3.74B 3.27B 3.02B 2.79B 5.29B 357B 5.38B 36.05B 14.16B 176B 14.04B 13.74B 604B EV / Sales 2026 *
2.54x
EV / Sales 2027 * 2.33x
Free-Float
32.48%
Yield 2026 *
3.17%
Yield 2027 * 4.16%
1 day-24.01%
6 months-24.01%
Current year-24.01%
Current year 1.49
Extreme 1.48945
1.49
1 year 1.49
Extreme 1.48945
1.96
3 years 0.69
Extreme 0.6922
1.96
5 years 0.69
Extreme 0.6922
1.96
10 years 0.69
Extreme 0.6922
1.96
Manager TitleAgeSince
Chief Executive Officer 54 25/03/2026
Director of Finance/CFO 55 19/11/2019
Chief Tech/Sci/R&D Officer 51 01/12/2023
Director TitleAgeSince
Chairman 63 08/10/2012
Director/Board Member 55 19/11/2019
Director/Board Member 46 01/11/2019
Change 5-day change 1-year change 3-year change Capi.($)
-24.01%-.--% - - 3.9B
-0.17%+1.61%+16.42%+85.22% 48.73B
+1.04%-1.02%+69.47%+115.88% 35.82B
-0.13%-1.29%-2.60%+41.58% 12.2B
-0.71%+0.89%+18.28%+97.87% 12.11B
-0.76%+0.38%+33.16%+123.08% 9.11B
-0.86%+0.37%+52.61%-3.54% 7.09B
+0.75%-0.82%+17.49%+44.79% 7B
+0.69%+3.25%+19.90%+243.91% 6.7B
+5.45%-7.36%-17.93%+13.17% 5.78B
Average -1.87%+0.11%+22.98%+84.66% 16.06B
Weighted average by Cap. -0.31%+0.39%+29.79%+90.75%

Financials

2026 *2027 *
Net sales 1.47B 1.29B 1.19B 1.1B 2.08B 140B 2.12B 14.19B 5.57B 69.18B 5.53B 5.41B 238B 1.67B 1.46B 1.34B 1.24B 2.36B 159B 2.4B 16.06B 6.31B 78.3B 6.26B 6.12B 269B
Net income 241M 211M 194M 180M 341M 22.98B 346M 2.32B 912M 11.32B 905M 885M 38.92B 283M 247M 228M 211M 400M 26.98B 407M 2.73B 1.07B 13.29B 1.06B 1.04B 45.69B
Net Debt -221M -193M -178M -164M -312M -21.04B -317M -2.13B -835M -10.36B -828M -810M -35.62B -84.71M -74.09M -68.34M -63.12M -120M -8.08B -122M -817M -321M -3.98B -318M -311M -13.68B
Logo Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces various drugs, including Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
7,038
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.46CNY
Average target price
15.42CNY
Spread / Average Target
+47.44%

Annual profits - Rate of surprise